PP
CGON icon

PDT Partners’s CG Oncology CGON Stock Holding History

PDT Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,182
Closed -$757K – 521
2026
Q1 		$757K Sell
11,182
-28,785
-72% -$1.63M 0.04% 371
2025
Q4 		$1.66M Hold
39,967
– – 0.11% 281
2025
Q3 		$1.61M Sell
39,967
-32,176
-45% -$935K 0.1% 293
2025
Q2 		$1.88M Buy
72,143
+4,426
+7% +$107K 0.11% 312
2025
Q1 		$1.66M Buy
+67,717
New +$1.9M 0.12% 296

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PDT Partners's CGON Position: Q2 2026 in Review

PDT Partners sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 11,182 shares — an estimated $757K sold.

PDT Partners first reported a position in CGON in Q1 2025 and held it in 5 quarters. The position peaked at $1.88M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • PDT Partners reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 11,182 CG Oncology shares in Q2 2026, an estimated $757K.
  • PDT Partners first reported a position in CG Oncology in Q1 2025 and held it in 5 quarters.
  • PDT Partners's CG Oncology position peaked at $1.88M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.